Cantor Fitzgerald Says Arrowhead Pharma's (ARWR) RNAi Deal with Amgen Validates Platform; Affirms at 'Buy'
Tweet Send to a Friend
Cantor Fitzgerald affirms Arrowhead Pharmaceuticals Inc. (Nasdaq: ARWR) at Buy with a price target of $15 following its RNAi program ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
